Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12029-013-9531-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tyrosine Kinase Inhibitor Treatment Patterns in Patients With Chronic-Phase Chronic Myeloid Leukemia: A Single Center Data From China.
Clin Lymphoma Myeloma Leuk
December 2024
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China; Hematology Center, Peking University People's Hospital, Qingdao, China. Electronic address:
Aim: To describe tyrosine kinase inhibitor (TKI) treatment patterns and analyze co-variates of TKI switch for chronic myeloid leukemia (CML) patients in a center from China.
Methods: A retrospectively study was designed to analyze TKI switching patterns, reasons and associated covariates in patients with CP-CML.
Results: 1766 patients receiving initial imatinib (n = 1374), nilotinib (n = 254), dasatinib (n = 63) and flumatinib (n = 75) therapy were retrospectively interrogated.
Introduction: This study aimed to analyze the survival outcomes and adverse events (AEs) associated with the long-term use of tyrosine kinase inhibitors (TKIs) and to assess health-related quality of life (HRQoL) in patients with chronic myeloid leukemia (CML).
Methods: Medical records of 345 patients with CML treated with at least one type of TKI were retrospectively reviewed.
Results: No significant differences in survival were observed based on the number of different TKIs the patients received (p = 0.
Low-dose Imatinib Efficacy in a Gastrointestinal Stromal Tumor Patient With Exon 11 W557_K558 Deletion.
In Vivo
December 2024
Department of Medical Oncology, Hyogo Cancer Center, Akashi, Japan.
Article Synopsis
- Gastrointestinal stromal tumors (GISTs) are rare cancers linked to mutations in the c-KIT gene, with one common mutation being a deletion in exon 11, as seen in an 82-year-old male patient diagnosed in June 2023.
- The patient subsequently received a low-dose imatinib treatment protocol, starting at 400 mg/day and tapering down to 200 mg/day, which resulted in a reduction of the tumor size over several months.
- The study suggests that low-dose imatinib can be an effective treatment option for GIST patients with the W557_K558 deletion, especially for those who cannot tolerate higher doses.
Population modelling of nilotinib exposure vs. longitudinal BCR::ABL1 response in patients with chronic phase chronic myeloid leukaemia using a semimechanistic disease model.
Br J Clin Pharmacol
December 2024
Novartis Pharma AG, Basel, Switzerland.
Aims: This study aims to evaluate the exposure-efficacy relationship of nilotinib and longitudinal BCR::ABL1 levels in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (CML-CP) and those who are imatinib-resistant or intolerant using a semimechanistic disease model.
Methods: The analysis included 489 CML-CP patients from 3 nilotinib trials (NCT00109707; NCT00471497; NCT01043874) with duration of follow-up ranging from 2 to 9 years. The semimechanistic disease model of CML-CP consisted of quiescent leukaemic stem cells, proliferating drug-susceptible and -resistant bone marrow cells.
Mebendazole effectively overcomes imatinib resistance by dual-targeting BCR/ABL oncoprotein and β-tubulin in chronic myeloid leukemia cells.
Korean J Physiol Pharmacol
January 2025
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Article Synopsis
- Tyrosine kinase inhibitors (TKIs) are key treatments for chronic myeloid leukemia (CML), but resistance and intolerance to these drugs pose significant challenges.
- This research highlights the potential of re-purposed drug mebendazole (MBZ) as an effective anti-cancer agent that can work against both imatinib-sensitive and imatinib-resistant CML cells.
- MBZ was found to inhibit cell proliferation and induce cell death by targeting BCR/ABL activity, disrupting microtubule formation, and increasing DNA damage, presenting a novel approach for treating TKI-resistant CML patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!